We recognize that there is a social interest in having that type of information to be used as peer assessment, to be used as aggregate data, to be used for research and planning, and to do so with suitable oversight by regulatory authorities. But what we want to prevent is the commercial use of that kind of information by private interests for marketing research. Under the appropriate regulations, such as those they would come under, we feel that medical licensing authorities, or pharmacy regulating boards in individual provinces, and research boards are what should be regulating these types of uses of that data.
On December 13th, 2006. See this statement in context.